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Abstract. 
With the growing use of immunotherapy in the treatment of cancer and autoimmune dis-
ease, severe autoimmune thyroid dysfunction may be provoked at an increasing rate. We herein 
report a 49-year-old male patient experiencing a life- threatening thyroid storm provoked by 
interleukin-2 (IL-2). This was a case of pulmonary metastasis of melanoma without a previous 
history of thyroid dysfunction. For the metastatic melanoma, he underwent combined immu-
nochemotherapy including dacarbazine and IL-2. The 3rd course of immunochemotherapy was 
complicated with a thyroid storm manifested by high fever, tachycardia and even transient car-
diac arrest. Fortunately, he recovered eventually from this crisis by immediate resuscitation 
followed by antithyroid dugs. Our case highlights the rare complication of a thyroid storm 
provoked by IL-2 treatment. Precaution against autoimmune thyroid dysfunction is required 
during treatment with IL-2 and probably also other kinds of newly-developed immunotherapy 
to avoid life-threatening complications. 
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中文摘要 
  隨著使用越來越多的免疫療法用在治療癌症和自身免疫性疾病方面，治療後引發嚴
重的自身免疫性甲狀腺功能障礙情況可能也隨之增多。因此，我們報導了一位 49 歲的男
性患者使用白細胞介素-2 (interleukin-2)治療轉移性黑色素瘤後引發之危及生命的甲狀腺
風暴病例。病患本身是一位黑色素瘤併肺轉移患者，並無過去甲狀腺功能異常病史。對
journal homepage:www.cos.org.tw/web/index.asp
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 於病患的轉移性黑色素瘤，他接受合併免疫藥物合併化學治療  (interleukin-2+ 
dacarbazine)。在第三次接受免疫化療過程中，產生甲狀腺風暴症狀與情況，其表現為發
燒，心動過速，甚至短暫的心臟停止。幸運的是，在抗甲狀腺藥物治療後，他終於從這
次甲狀腺風暴中恢復。我們的病例焦點在白細胞介素-2 (interleukin-2) 治療後引發之罕見
甲狀腺風暴的併發症。為避免危及生命的併發症產生，所以在使用 interleukin-2 或一些新
發展的免疫治療時，更須注意免疫性甲狀腺功能異常產生之狀況。 
 
關鍵字: 免疫治療、白細胞介素-2、黑色素瘤、甲狀腺風暴 
INTRODUCTION 
The thyroid storm is a rare but life-threatening 
condition [1], which is a medical emergency precipi-
tated by antineoplastic agents, physical stress, infec-
tion, noncompliance to antithyroid medications, trau-
ma, or radiotherapy [2,3]. The incidence of a thyroid 
storm following thyrotoxicosis is estimated to be less 
than 10% in hospitalized patients [4]. However, the 
mortality rate ranges from 20 to 30% [4]. Some newer 
antineoplastic agents such as targeted therapies and 
immunotherapies lead to thyroid dysfunction in 20 to 
50% patients [2,5]. IL-2 therapy is associated with 
transient painless thyroiditis in about 20% of patients 
[6]. However, the severity of thyroid dysfunction is 
significantly correlated with treatment duration and 
the cumulative dose of IL-2 [6]. Hypothyroidism oc-
curs in 35% of patients receiving IL-2 therapy alone, 
and hyperthyroidism develops in 7% of patients re-
ceiving high-dose IL-2. Overall, the incidence of thy-
roid dysfunction is influenced by the dosage of IL-2 
between the high- and low-dose IL-2 regimens [7]. 
We report a rare case of metastatic melanoma 
without any history of thyroid disorder. Unfortunately, 
a thyroid storm occurred after regular treatment with 
IL-2 and dacarbazine immunochemotherapy. However, 
thanks to a favorable response to anti-thyroid drugs 
and medical treatment, the patient survived, and re-
covered from multiple organ failure one month later. 
 
CASE REPORT 
A 49-year-old man initially presented with a 
chronic wound on the right middle finger for 2 months 
since November 2009. He had a history of hyperten-
sion and mild mitral valve prolapse under medication 
for 5 years. He underwent an excisional biopsy with 
disarticulation of the right middle finger and a sentinel 
lymph node biopsy of the right axilla in January 2010. 
The pathological findings suggested malignant mela-
noma without sentinel lymph node involvement. 
Whole body Positron Emission Tomography (PET) 
showed no other evidence of hypermetabolic lesions. 
A whole body bone scan failed to show any active 
bone lesion. Chest computed tomography (CT) in 
November 2010 revealed a 0.6 cm subpleural nodule 
in the right lower lung, which showed progression 
from 0.6 to 0.8 cm ten months later. Therefore, thora-
coscopic wedge resection was performed in October 
2011. Metastatic melanoma with immunoreactive 
findings for S100, HMB45 and melan-A was con-
firmed by the pathologic examination. Focal PET/CT 
for the upper torso showed negative results for a hy-
permetabolic lesion. Therefore, he was referred to an 
oncologist for advanced therapy. 
The treatment regimen for each 3-week cycle con-
sisted of dacarbazine (750 mg/m2) for 1 day and fixed 
dose of IL-2 with subcutaneous injected 18MU every 
12 hours for 2 days. Intermittent mild fever up to 
37.5ºC or tachycardia up to 110/min were complained  
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 of during the period of IL-2 injection. The fever sub-
sided after completion of IL-2 injection and the use of 
antipyretics. Electrocardiography (EKG) showed a 
normal sinus rhythm. During the third cycle in De- 
Table 1. Burch and Wartofsky’s scoring system 
Diagnostic parameters Scoring points 
Thermoregulatory dysfunction; Temperature F (°C) 
99-99.9 (37.2-37.7) 
100-100.9 (37.8-38.2) 
101-101.9 (38.3-38.8) 
102-102.9 (38.9-39.2) 
103-103.9 (39.3-39.9) 
≥104.0 (≥40.0) 
 
5 
10 
15 
20 
25 
30 
Cardiovascular dysfunction 
Tachycardia (beats/minute) 
90-109 
110-119 
120-129 
130-139 
≥140 
 
 
5 
10 
15 
20 
25 
Congestive heart failure 
Absent  
Mild (pedal edema)  
Moderate (bibasilar rales)  
Severe (pulmonary edema) 
 
0 
5 
10 
15 
Atrial fibrillation 
Absent  
Present  
 
0 
10 
Central nervous system symptoms 
Absent  
Mild (agitation)  
Moderate (delirium, psychosis, extreme lethargy  
Severe (seizures, coma) 
 
0 
10 
20 
30 
Gastrointestinal-hepatic dysfunction 
Absent  
Moderate (diarrhea, nausea/vomiting, abdominal pain)  
Severe (unexplained jaundice) 
 
0 
10 
20 
Precipitating event 
Absent  
Present  
 
0 
10 
Patient’s scores: 30(40°C)+25 (140/min)+30(coma)+5(Pedal edema)+10(precipitant event)=100 
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Figure 1. Change of body temperature and heart rate after anti-thyroid drugs 
 
 
cember 2011, his vital sign was BT:36.8ºC, BP:118/64 
mmHg, HR:105/min and RR:17/min initially. Blood 
analysis revealed WBC:7900/cumm, Hb:11.1g/dl and 
PLT:216000/cumm. Biochemical data were also with-
in normal limits. A high fever up to 38.9ºC developed, 
with tachycardia up to 147/min seven hours after IL-2 
injection. Unfortunately, loss of consciousness and 
pulses, and relapsed fever were found four hours later. 
Immediated cardiopulmonary and fluid resuscitation 
including inotropic agents, and airway support with an 
endotracheal tube insertion and mechanical ventilation 
were administered. Immediate cardioversion for ven-
tricular tachycardia was also performed, which suc-
ceeded in restoring a sinus rhythm and spontaneous 
circulation about one hour later. Then, he was trans-
ferred to the intensive care unit (ICU), where bedside 
echocardiography showed normal contractibility and 
preserved left ventricular ejection fraction. Persistent 
sinus tachycardia and fever up to 40ºC were still no-
ticed. Blood culture showed no growth. No infectious 
focus, pleural effusion or cardiomegaly was noted. 
Acute renal and hepatic failure gradually occurred in 
ICU. Analysis of thyroid function showed: thy-
roid-stimulating hormone (TSH):0.032 uIU/ml, and 
free T4:6.59 ng/dl (normal range: TSH:0.4-4.0 uIU/ml; 
free T4:0.8-1.9 ng/dl). Anti-thyroid antibodies includ-
ing anti-thyroglobulin (aTG) antibody:111.6 U/ml and 
TSH receptor antibody (TSH-R-Ab):12% were de-
tected (normal range: aTG:<60 U/ml; TSH-R-Ab: 
<3%). Anti-thyroid peroxidase (aTPO) was within the 
normal range. As the scoring criteria of Burch and 
Wartofsky, a cumulative score system of 45 or more is 
highly suggestive of a thyroid storm; 25-44 is sugges-
tive of an “impending” storm and a score below 25 is 
unlikely to represent thyroid storm [1]. We consulted 
an Endocrinologist, who confirmed the diagnosis of 
thyroid storm by the scoring criteria of Burch and 
Wartofsky with a score of 100, including temperature 
up to 40ºC, tachycardia up to 140/min, coma, pedal 
edema and precipitant history (Table 1). Initially, we 
treated him with hydrocortisone 100 mg IV q8h, 
propylthiouracil 150 mg PO q6h and propranolol 10 mg  
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Figure 2. Thyroid functions after thyroid storm. Thyroid storm occurred on 
Day 0 and propylthiouracil was given since Day 1 
 
 
PO q8h. Tachycardia, fever and poor consciousness 
improved after anti-thyroid drugs (Figure 1). Suc-
cessful extubation was performed 3 days later after 
anti-thyroid drugs. A sequential follow-up of thyroid 
function and organ failure also showed improvement 
(Figure 2). Thyroid echography revealed an enlarged 
thyroid gland on the left and a small echogenic nodule 
in the right lobe. Finally, the patient recovered from 
multiple organ failure and was discharged one month 
later in good condition.   
 
DISCUSSION 
Graves’ disease is the most common cause of a 
thyroid storm [1,8]. Other causes of thyrotoxicosis 
leading to the thyroid storm include thyroid cancer, 
pituitary adenoma, struma ovarii or teratoma , trauma, 
physical stress, noncompliance to antithyroid medica-
tions or radiotherapy [5,9,10]. Rare causes, such as 
interferon alpha (INF-α), IL-2, viral hepatitis or HIV 
infection, are also associated with thyrotoxicosis 
[10,11]. Immunotherapy with IL-2 may induce thyro-
toxicosis while no crisis-induction has been reported 
[10,11]. Krouse et al. reported the 35% of patients re-
ceiving IL-2 immunotherapy developed hypothyroid-
ism, while only 7% developed hyperthyroidism and 
no case of thyrotoxicosis crisis [8]. In another series 
including 130 patients with cancer, hypothyroidism 
occurred with incidences of 12%, 38% and 23% be-
fore, during, and after IL-2- based therapy while hy-
perthyroidism developed in 1%, 4% and 7% at those 
time intervals, respectively [11]. Therefore, this is 
probably the first time in the literature to report that 
IL-2 precipitated a thyroid storm in a case of Graves’ 
disease undiagnosed before. 
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 IL-2 is a cytokine approved to treat melanoma and 
renal cell cancer. The pharmacological mechanism to 
kill tumor cells is mediated through activation of nat-
ural killer cells and antigen-specific T-cells [4,11]. It 
has shown to induce altered thyroid function by an 
increase of thyroid autoantibody and infiltrating auto-
reactive lymphocytes in thyroid gland, leading to au-
toimmune hyperthyroidism or hypothyroidism [4,12- 
14]. In one article by Vialettes et al. thyroid function 
were measured serially in 146 consecutive patients 
with a refractory solid tumor or hematological malig-
nancy treated by recombinant IL-2 (rIL-2). Peripheral 
hypothyroidism occurred upon entry in nine patients. 
Thyroid dysfunction appeared or worsened during 
rIL-2 therapy in 24 (16.4%) patients. Sixteen (10.9%) 
patients presented peripheral hypothyroidism and an-
other five (3.4%) patients developed transient hyper-
thyroidism [12]. In that study, thyroid dysfunction ap-
peared early after one or two cycles and only gender 
and presence of antithyroid antibody were correlated 
significantly with rIL-2-induced thyroid abnormalities 
in 60.9% of patients [12]. In our case, we also found 
the similar abnormal presentations of antithyroid an-
tibodies and timing of thyroid dysfunction. Thyroid 
dysfunction usually appears 4-17 weeks or after one or 
two cycles of therapy [12,15]. Besides, in most reports, 
aTG antibody and antithyroid microsomal antibody 
(AMA) can be detected, suggesting an autoimmune 
basis for the thyroid dysfunction [16,17]. 
As far as we know, we have the first time in the 
literature presented a case of thyroid storm precipitat-
ed from Graves’ disease undiagnosed before, during 
the 3rd cycle of IL-2-combined therapy. The IL-2-  
induced hyperthyroidism was much more severe much 
more than in other cases reported before, probably due 
to preexisting high titers of aTG antibody and TSH-R- 
Ab. Although immunotherapy-induced thyroid dys-
function, especially with hyperthyroidism, caused by 
immunotherapy is rare, it can be life-threatening. We 
therefore recommend a routine check of thyroid func-
tion and anti-thyroid antibodies before initiation of 
IL-2 therapy or other newly launched immunothera-
pies and a monitoring with appropriate data during 
treatment. 
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